Ironwood Pharma (IRWD) Tops Q4 EPS by 7c, Offers FY Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Ironwood Pharma (IRWD) Tops Q4 EPS by 7c, Offers FY Guidance

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance

February 17, 2021 7:01 AM EST

LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5%

2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration revenue

2020 GAAP net income was $106 million and adjusted EBITDA was $161 million; ended 2020 with $363 million in cash and cash equivalents

Full year 2021 total revenue guidance of $370 to $385 million and adjusted EBITDA guidance of >$190 million

BOSTON--(BUSINESS... More